Key facts
- CurifyLabs’s last known valuation is $31.2M (May 2025).
- It has raised $11.3M; the latest was Equity Crowdfunding ($7.6M) in May 2025.
- Notable investors include European Innovation Council, European Union, Lifeline Ventures, Nordic Mentor Network For Entrepreneurship, Excedea Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for CurifyLabs
- ·The full record, as it builds
Funding rounds
No funding rounds for CurifyLabs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CurifyLabs
Developer of a compounding system designed to bring consistency, safety, and speed to personalized medicine preparation.The company offers proprietary software, GMP (Good Manufacturing Practice)-manufactured excipients, and advanced 3D (three dimensional) printing technology, enabling hospitals and pharmacies to deliver precise, individualized treatments efficiently.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Founded
- 2021
- Employees
- 33
- Website
- curifylabs.com/
- Ownership
- Privately Held (backing)
CurifyLabs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CurifyLabs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CurifyLabs in its N-PORT filings yet. We sweep new filings monthly.